Evoke Pharma, Inc. (EVOK)
Market Cap | 7.09M |
Revenue (ttm) | 2.51M |
Net Income (ttm) | -8.22M |
Shares Out | 3.34M |
EPS (ttm) | -2.62 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 29,822 |
Open | 2.27 |
Previous Close | 2.28 |
Day's Range | 2.00 - 2.32 |
52-Week Range | 1.37 - 16.80 |
Beta | 0.40 |
Analysts | Buy |
Price Target | 7.14 (+236.79%) |
Earnings Date | May 9, 2023 |
About EVOK
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incor... [Read more]
Full Company ProfileFinancial Performance
In 2022, Evoke Pharma's revenue was $2.51 million, an increase of 55.04% compared to the previous year's $1.62 million. Losses were -$8.22 million, -3.68% less than in 2021.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for EVOK stock is "Buy." The 12-month stock price forecast is $7.14, which is an increase of 236.79% from the latest price.
News

Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023
Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI

Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021 Patient enrollment increased by 149% compared with 2021

Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023
SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...

Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
Distinguished event features the year's best abstracts and invited speakers in their fields Distinguished event features the year's best abstracts and invited speakers in their fields

Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti
Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023
Real-world study compares diabetic gastroparesis patient utilization of healthcare resources before and after initiation of GIMOTI Real-world study compares diabetic gastroparesis patient utilization ...

USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis
SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®
SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

Evoke Pharma to Report Third Quarter Results on November 9, 2022
SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced ...

Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting
Company will exhibit Gimoti® and meet with Key Opinion Leaders

Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI
SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...

GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award
GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies

Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today...

Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution
Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealth Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Trea...

Evoke Pharma Reports Second Quarter 2022 Financial Results
Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11% Total new inbound prescriptions over 500 for first time, ...

Evoke Pharma to Report Second Quarter Results on August 10, 2022
SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced ...

Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)
Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders

Evoke Pharma (EVOK) Stock Soars 50% on Medicaid Drug Approval
Evoke Pharma (EVOK) stock is rocketing higher on Wednesday after the company got Medicaid approval for its GIMOTI nasal spray. The post Evoke Pharma (EVOK) Stock Soars 50% on Medicaid Drug Approval ap...

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program
SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update
SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported
Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide

Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022
SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced t...

Why Is Evoke Pharma (EVOK) Stock Up 130% Today?
Evoke Pharma is up an unbelievable 130% today on news of recently granted drug exclusivity. How high will EVOK stock soar?

Evoke Shares Skyrocket On New FDA Market Exclusivity For Gimoti Nasal Spray
The FDA has granted new drug product exclusivity to Evoke Pharma Inc's (NASDAQ: EVOK) Gimoti (metoclopramide) nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis...

Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare pr...